C. Tibery

A prospective randomized pilot study to evaluate predictors of response in serial core biopsies to single agent neoadjuvant doxorubicin or paclitaxel for patients with locally advanced breast cancer.

Baljit Singh, C. Isaacs, D. Hayes, 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

A Live Attenuated Chimeric West Nile Virus Vaccine, rWN/DEN4&Dgr;30, Is Well Tolerated and Immunogenic in Flavivirus-Naive Older Adult Volunteers

A. Pletnev, K. Pierce, A. Durbin, 2017, The Journal of infectious diseases.

A single dose of any of four different live attenuated tetravalent dengue vaccines is safe and immunogenic in flavivirus-naive adults: a randomized, double-blind clinical trial.

B. Murphy, K. Subbarao, J. Lindow, 2013, The Journal of infectious diseases.

Robust and Balanced Immune Responses to All 4 Dengue Virus Serotypes Following Administration of a Single Dose of a Live Attenuated Tetravalent Dengue Vaccine to Healthy, Flavivirus-Naive Adults.

K. Subbarao, N. Hynes, K. Pierce, 2015, The Journal of infectious diseases.

Phase II trial of the MEK 1/2 inhibitor selumetinib (AZD6244, ARRY-142886 Hydrogen Sulfate) in adults with neurofibromatosis type 1 (NF1) and inoperable plexiform neurofibromas (PN).

L. Rubinstein, J. Doroshow, A. Chen, 2020 .

The MEK inhibitor selumetinib reduces spinal neurofibroma burden in patients with NF1 and plexiform neurofibromas.

A. Chen, E. Baker, B. Widemann, 2020, Neuro-oncology advances.

The live attenuated dengue vaccine TV003 elicits complete protection against dengue in a human challenge model

N. Hynes, K. Pierce, S. Diehl, 2016, Science Translational Medicine.

Evaluation of a new dengue 3 controlled human infection model for use in the evaluation of candidate dengue vaccines.

He He, K. Pierce, S. Diehl, 2023, medRxiv.

In a randomized trial, the live attenuated tetravalent dengue vaccine TV003 is well-tolerated and highly immunogenic in subjects with flavivirus exposure prior to vaccination

K. Subbarao, N. Hynes, K. Pierce, 2017, PLoS neglected tropical diseases.

A 12-Month-Interval Dosing Study in Adults Indicates That a Single Dose of the National Institute of Allergy and Infectious Diseases Tetravalent Dengue Vaccine Induces a Robust Neutralizing Antibody Response.

K. Subbarao, N. Hynes, K. Pierce, 2016, The Journal of infectious diseases.

The live attenuated dengue vaccine TV003 elicits complete protection against dengue in a human challenge model

K. Pierce, S. Diehl, A. Durbin, 2016, Science Translational Medicine.